Literature DB >> 28555303

The Evolution of Spina Bifida Treatment Through a Biomedical Ethics Lens.

Tal Levin-Decanini1,2, Amy Houtrow3, Aviva Katz4.   

Abstract

Spina bifida is a neurodevelopmental disorder that results in a broad range of disability. Over the last few decades, there have been significant advances in diagnosis and treatment of this condition, which have raised concerns regarding how clinicians prognosticate the extent of disability, determine quality of life, and use that information to make treatment recommendations. From the selective treatment of neonates in the 1970s, to the advent of maternal-fetal surgery today, the issues that have been raised surrounding spina bifida intervention invoke principles of medical bioethics such as beneficence and nonmaleficence, while also highlighting how quality of life judgments may drive care decisions. Such changes in treatment norms are also illustrative of how disability is viewed both within the medical community and by society at large. An examination of the changes in spina bifida treatment provides a model through which to understand how ethically complex decisions regarding care for children with disabilities has evolved, and the challenges faced when medical information is combined with value-based judgments to guide medical decision making.

Entities:  

Keywords:  Groningen Protocol; MOMS trial; Myelomeningocele; Spina bifida

Mesh:

Year:  2017        PMID: 28555303     DOI: 10.1007/s10730-017-9327-2

Source DB:  PubMed          Journal:  HEC Forum        ISSN: 0956-2737


  43 in total

Review 1.  Framework for teaching and learning informed shared decision making.

Authors:  A Towle; W Godolphin
Journal:  BMJ       Date:  1999-09-18

2.  Long-term outcome in open spina bifida.

Authors:  Pippa Oakeshott; Gillian M Hunt
Journal:  Br J Gen Pract       Date:  2003-08       Impact factor: 5.386

3.  The Groningen protocol--euthanasia in severely ill newborns.

Authors:  Eduard Verhagen; Pieter J J Sauer
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

4.  Making decisions for the severely handicapped newborn.

Authors:  J M Freeman
Journal:  J Health Polit Policy Law       Date:  1986       Impact factor: 2.265

5.  Care of infants with myelomeningocele.

Authors: 
Journal:  Pediatrics       Date:  1984-07       Impact factor: 7.124

6.  Contrasting parents' and pediatricians' perspectives on shared decision-making in ADHD.

Authors:  Alexander G Fiks; Cayce C Hughes; Angela Gafen; James P Guevara; Frances K Barg
Journal:  Pediatrics       Date:  2010-12-20       Impact factor: 7.124

7.  A randomized trial of prenatal versus postnatal repair of myelomeningocele.

Authors:  N Scott Adzick; Elizabeth A Thom; Catherine Y Spong; John W Brock; Pamela K Burrows; Mark P Johnson; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Leslie N Sutton; Nalin Gupta; Noel B Tulipan; Mary E D'Alton; Diana L Farmer
Journal:  N Engl J Med       Date:  2011-02-09       Impact factor: 91.245

8.  A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida.

Authors:  Frank A Chervenak; Laurence B McCullough
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

9.  Results of selective treatment of spina bifida cystica.

Authors:  J Lorber; S A Salfield
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791

Review 10.  Deliberate termination of life of newborns with spina bifida, a critical reappraisal.

Authors:  T H Rob de Jong
Journal:  Childs Nerv Syst       Date:  2007-10-10       Impact factor: 1.475

View more
  2 in total

1.  Introduction: Childhood and Disability.

Authors:  Erica K Salter
Journal:  HEC Forum       Date:  2017-09

2.  Intra-amniotic transplantation of brain-derived neurotrophic factor-modified mesenchymal stem cells treatment for rat fetuses with spina bifida aperta.

Authors:  Wei Ma; Xiaowei Wei; Hui Gu; Dan Liu; Wenting Luo; Songying Cao; Shanshan Jia; Yiwen He; Lizhu Chen; Yuzuo Bai; Zhengwei Yuan
Journal:  Stem Cell Res Ther       Date:  2022-08-13       Impact factor: 8.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.